An oral drug approved for the treatment of Hepatitis C?
**Core Concept**
The treatment of Hepatitis C involves targeting the viral replication process. Direct-acting antivirals (DAAs) have revolutionized the management of HCV, offering improved efficacy and reduced side effects compared to older therapies like interferon and ribavirin.
**Why the Correct Answer is Right**
Sofosbuvir is a potent HCV NS5B polymerase inhibitor. It works by binding to the NS5B enzyme, which is essential for the replication of the HCV genome. By inhibiting this enzyme, Sofosbuvir prevents the viral RNA from being replicated, ultimately reducing the viral load in the body. Sofosbuvir is often used in combination with other DAAs, such as ledipasvir, to achieve high cure rates and minimize the risk of resistance.
**Why Each Wrong Option is Incorrect**
**Option A:** Telaprevir is a NS3/4A protease inhibitor, but it has been largely replaced by more effective and better-tolerated DAAs like Sofosbuvir.
**Option B:** Boceprevir is another NS3/4A protease inhibitor, but it has similar limitations to Telaprevir and is not as effective as Sofosbuvir.
**Option C:** Ribavirin is an older antiviral medication that works by inducing mutagenesis in viral RNA, but it is often used in combination with interferon and DAAs like Sofosbuvir.
**Clinical Pearl / High-Yield Fact**
Sofosbuvir-based regimens have a high cure rate (>90%) for most HCV genotypes, making it a first-line treatment option for many patients. Its efficacy and safety profile have transformed the management of Hepatitis C.
**Correct Answer: C. Sofosbuvir**